• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc. (Amendment)

    2/13/23 8:07:36 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRVI alert in real time by email
    SC 13G/A 1 s60895698a.htm SCHEDULE 13G/A, AMENDMENT #3


    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 3)*





    Maravai LifeSciences Holdings, Inc.

    (Name of Issuer)


    Class A Common Stock

    (Title of Class of Securities)



    56600D107

    (CUSIP Number)


    December 31, 2022

    (Date of Event Which Requires Filing of This Statement)




    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     
    ☒
    Rule 13d-1(b)
     
    ☐
    Rule 13d-1(c)
     
    ☐
    Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




    CUSIP No. 56600D107
    SCHEDULE 13G
    Page 2 of 6

    1
    NAMES OF REPORTING PERSONS
     
    Select Equity Group, L.P.
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)     ☐
    (b)     ☐
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
     
     
     
     
    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,524,793
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,524,793
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    2,524,793
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.9%*
    12
    TYPE OF REPORTING PERSON
     
    IA

    * Beneficial ownership based on 131,539,642  shares of Class A common stock outstanding as of October 28, 2022 and 123,669,196 shares of Class B common stock outstanding as of October 28, 2022, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2022.


    CUSIP No. 56600D107
    SCHEDULE 13G
    Page 3 of 6

    1
    NAMES OF REPORTING PERSONS
     
    George S. Loening
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) ☐
    (b) ☐
    3
    SEC USE ONLY


    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    USA
     
     
     
     
    NUMBER
    OF SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    2,524,793
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    2,524,793
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH PERSON
     
    2,524,793
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
    ☐
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    1.9%*
    12
    TYPE OF REPORTING PERSON
     
    IN/HC
    * Beneficial ownership based on 131,539,642  shares of Class A common stock outstanding as of October 28, 2022 and 123,669,196 shares of Class B common stock outstanding as of October 28, 2022, as reported on the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on November 3, 2022.



    Item 1(a)
    Name of Issuer:
       
     
    Maravai LifeSciences Holdings, Inc.
       
    Item 1(b)
    Address of Issuer’s Principal Executive Offices:
       
     
    10770 Wateridge Circle, Suite 200
     
    San Diego, California, 92121
       
    Items 2(a)
    Name of Person Filing:
       
     
    This Schedule 13G is being filed jointly by Select Equity Group, L.P., a Delaware limited partnership (“Select LP”), and George S. Loening (“Loening”), who is the majority owner of Select LP and managing member of its general partner. Select LP and Loening are sometimes jointly referred to herein as the “Select Reporting Persons.”
       
    Item 2(b)
    Address of Principal Business Office:
     
    The business address of each of the Select Reporting Persons is:

    380 Lafayette Street, 6th Floor
    New York, New York 10003.
       
    Item 2(c)
    Citizenship:
       
     
    George S. Loening is a United States citizen.
       
    Item 2(d)
    Title of Class of Securities:
       
     
    Class A Common Stock
       
    Item 2(e)
    CUSIP Number:
       
     
    56600D107

    Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is:

    (a)
    ☐ Broker or dealer registered under Section 15 of the Act;
    (b)
    ☐ Bank as defined in Section 3(a)(6) of the Act;
    (c)
    ☐ Insurance company as defined in Section 3(a)(19) of the Act;
    (d)
    ☐ Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)
    ☒ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)
    ☐ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)
    ☒ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)
    ☐ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)
    ☐ A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)
    ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).



    Item 4
    Ownership:
       
     
    The information required by Items 4(a)-(c), as of the date hereof, is set forth in Rows 5-11 of the cover page hereto for each Select Reporting Person and is incorporated herein by reference for each such Select Reporting Person.
       
    Item 5
    Ownership of Five Percent or Less of a Class:
       
     
    If this statement is being filed to report the fact that as of the date hereof a reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☒.
       
    Item 6
    Ownership of More than Five Percent on Behalf of Another Person:
       
     
    N/A
       
    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
     
    See Exhibit 99.1.
       
    Item 8
    Identification and Classification of Members of the Group:
       
     
    N/A
       
    Item 9
    Notice of Dissolution of Group:
       
     
    N/A
       
    Item 10
    Certification:
       
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.



    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.


     
    SELECT EQUITY GROUP, L.P.
       
     
    By: Select Equity GP, LLC, its General Partner
     
    By:
     /s/ George S. Loening
     
    Name: George S. Loening
     
    Title: Managing Member
         
         
         
       /s/ George S. Loening
     
    George S. Loening, an individual


    Dated: February 14, 2023



    Get the next $MRVI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MRVI

    DatePrice TargetRatingAnalyst
    2/26/2025$9.00 → $3.00Outperform → Neutral
    Robert W. Baird
    12/19/2024Neutral
    Guggenheim
    12/5/2024$4.25Neutral → Sell
    Goldman
    11/14/2024Peer Perform
    Wolfe Research
    11/8/2024Outperform → Mkt Perform
    William Blair
    8/28/2024$10.00Overweight
    Wells Fargo
    8/13/2024$11.00 → $10.00Overweight → Equal-Weight
    Morgan Stanley
    4/10/2024$15.00Buy
    Craig Hallum
    More analyst ratings

    $MRVI
    SEC Filings

    View All

    SEC Form 10-K filed by Maravai LifeSciences Holdings Inc.

    10-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

    2/26/26 4:06:12 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Filer)

    2/25/26 4:05:08 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Maravai LifeSciences Holdings Inc.

    SCHEDULE 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

    2/17/26 10:30:13 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maravai Life Sciences downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Maravai Life Sciences from Outperform to Neutral and set a new price target of $3.00 from $9.00 previously

    2/26/25 7:15:06 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Maravai Life Sciences

    Guggenheim initiated coverage of Maravai Life Sciences with a rating of Neutral

    12/19/24 8:13:54 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai Life Sciences downgraded by Goldman with a new price target

    Goldman downgraded Maravai Life Sciences from Neutral to Sell and set a new price target of $4.25

    12/5/24 7:46:04 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Dolan Christine covered exercise/tax liability with 28,934 shares, decreasing direct ownership by 6% to 448,973 units (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    1/20/26 5:28:35 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    General Counsel Oreshack Kurt covered exercise/tax liability with 31,902 shares, decreasing direct ownership by 7% to 424,967 units (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    1/20/26 5:28:30 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lucier Gregory T bought $368,544 worth of shares (100,000 units at $3.69), increasing direct ownership by 181% to 155,123 units (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    12/9/25 4:36:29 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

    Organizational restructuring and operating cost reduction ahead of plan Focus on operational excellence, revenue growth, and improving Adjusted EBITDA Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of $(31.2) millio

    2/25/26 4:01:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

    Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai M

    2/9/26 5:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences Announces November 2025 Investor Conference Schedule

    Maravai LifeSciences, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of November. On November 12, 2025, at 10:00 a.m. EST, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Stifel Healthcare Conference in New York City, NY. On November 19, 2025, at 10:00 a.m. GMT, Raj Asarpota, Chief Financial Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in London, England. A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investo

    11/10/25 8:00:00 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lucier Gregory T bought $368,544 worth of shares (100,000 units at $3.69), increasing direct ownership by 181% to 155,123 units (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    12/9/25 4:36:29 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Brust Bernd bought $702,689 worth of shares (216,212 units at $3.25) (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    11/17/25 4:48:14 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Brust Bernd bought $809,010 worth of shares (250,559 units at $3.23) (SEC Form 4)

    4 - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Issuer)

    11/13/25 5:27:45 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Financials

    Live finance-specific insights

    View All

    Maravai Lifesciences Reports Fourth Quarter and Full Year 2025 Financial Results

    Organizational restructuring and operating cost reduction ahead of plan Focus on operational excellence, revenue growth, and improving Adjusted EBITDA Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the fourth quarter and full year ended December 31, 2025, together with other business updates. Key Financial Results: Quarterly revenue of $49.9 million, Net loss of $(63.0) million, and Adjusted EBITDA (non-GAAP) of $0.5 million; Annual revenue of $185.7 million, Net loss of $(230.8) million and Adjusted EBITDA (non GAAP) of $(31.2) millio

    2/25/26 4:01:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences To Host Earnings Conference Call on Wednesday, February 25, 2026

    Maravai LifeSciences, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2025 financial and operating results after the market close on Wednesday, February 25, 2026, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial 1-800-343-4136 or 1-203-518-9843 and reference Maravai LifeSciences, Conference ID: MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com. About Maravai M

    2/9/26 5:05:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences Reports Third Quarter 2025 Financial Results

    Organizational restructuring and operating cost reduction initiatives on track Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the third quarter ended September 30, 2025, together with other business updates. Quarterly Results: Revenue of $41.6 million, Net loss of $(45.1) million, and Adjusted EBITDA of $(10.8) million "We exited the third quarter confident about the future of our business. Cygnus continues to perform well and TriLink, although lumpy by nature, shows strong funnel and order velocity. We expect TriLink to deliver double digit

    11/6/25 4:01:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Leadership Updates

    Live Leadership Updates

    View All

    Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer

    SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh "Raj" Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  "We thank Kevin for his commitment to Maravai and his leadership over the past eight years," said Susannah Gray, Audit Committee Chair, Maravai Board of Directors. "He has played an important role in shaping the company's foundati

    6/25/25 4:01:00 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors

    SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William "Trey" Martin III in these roles. "This leadership transition reflects Maravai's commitment to accelerating innovation, execution, and financial performance. Bernd brings more than 30 years of leadership experience in the life sciences industry, with a proven track record of transforming businesses into profitable, revenue-growing com

    6/9/25 8:30:00 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

    Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of "Maravai LifeSciencesReleases 2024 Sustainability Report". The corrected title is "Maravai LifeSciences Releases 2024 Sustainability Report". Maravai Lif

    5/21/25 4:22:17 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MRVI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

    SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

    11/14/24 7:49:19 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

    SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

    11/13/24 4:48:49 PM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Maravai LifeSciences Holdings Inc.

    SC 13G/A - MARAVAI LIFESCIENCES HOLDINGS, INC. (0001823239) (Subject)

    11/13/24 9:30:19 AM ET
    $MRVI
    Biotechnology: Pharmaceutical Preparations
    Health Care